Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

CO-1686 Receives Breakthrough Designation for EGFR T790M-Positive NSCLC

May 20th 2014

CO-1686 has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic T790M mutation-positive NSCLC who have received at least one prior line of EGFR-targeted therapy.

Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC

May 20th 2014

A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology, a retrospective study of patient data showed.

AZD9291 Shows Robust Activity in Resistant EGFR-positive NSCLC

May 14th 2014

The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.

Targeting CD19 May Yield Paradigm-Altering Technology

May 9th 2014

For the past two decades, researchers have been exploring B-cell specific antigens in hopes of developing a new anticancer target that would mirror the success of the CD20-targeting rituximab (Rituxan). Now, strategies aimed at CD19 are proving particularly promising.

Dr. Salerno on Donations to Breast Cancer Research

May 7th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, comments on donations to breast cancer research.

New Options for Low-Risk, HER2-Positive Tumors Featured in Research Overview

May 7th 2014

Fresh insights into outcomes for patients with low-risk, HER2-positive breast cancer suggest that adjuvant chemotherapy regimens with or without trastuzumab (Herceptin) should be considered as options for managing this growing population

Dr. Younes Discusses the Future of Treating Lymphoid Malignancies

May 6th 2014

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.

New PER Conference Debuts With Format Aimed at Pressing Clinical Issues

May 1st 2014

Leading experts in the rapidly evolving field of lung cancer treatment assembled to offer their perspectives on the latest research and provide clinical insights for practitioners dealing with challenging cases.

Tackling Tumor Sampling: Technical Advances May Help Optimize Molecularly Targeted Treatment Strategies

April 29th 2014

It seems that rarely a month goes by these days without the publication of a major study demonstrating the impact of fresh knowledge regarding molecular abnormalities in a particular tumor type.

Dr. Halmos on the Impact of EGFR Inhibitors on the Treatment of Lung Cancer

April 28th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the impact of EGFR inhibitors on the treatment of lung cancer.

Docs Hesitant to Embrace Genomic Tests

April 28th 2014

A physician's confidence level in his genomic knowledge plays a significant role in attitudes towards genomic tests, especially in tests that look for changes in DNA that are taken from patients' tumor samples

Researchers Focus on Optimizing Radiotherapy for Locally Advanced NSCLC

April 24th 2014

Locally advanced non-small cell lung cancer (NSCLC) remains a challenging disease to treat, with a 5-year survival rate for patients with unresectable stage III disease of approximately 20%, even after definitive radiation therapy and concurrent chemotherapy.

Dr. Kunz on Identifying Gastric Cancer Subtypes

April 23rd 2014

Pamela L. Kunz, MD, assistant professor of medicine, Oncology, Stanford University Medical Center, discusses the effort to identify molecular subtypes of gastric cancer.

Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study

April 23rd 2014

A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma

Ellen T. Matloff on Changes to the Field of Genetic Testing

April 22nd 2014

Ellen T. Matloff, MS, CGC, director, Yale Cancer Genetic Counseling Program at the Yale School of Medicine/Yale Cancer Center, gives an overview of the recent changes to the field of genetic testing.

Emerging Breakthroughs in Cancer Care: Toward a Revolution?

April 21st 2014

Medicine is undergoing a revolution that will transform the practice of healthcare, including oncology.

Dr. Melnick on Targeting EZH2 in DLBCL

April 10th 2014

Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.

Targeted Therapies Usher in a New Era in CLL: Wierda Discusses Key Facets of Emerging Agents

April 4th 2014

The approval of the first small-molecule, targeted therapy for patients with chronic lymphocytic leukemia (CLL) launches a new era that promises to transform management of the disease, yet significant challenges in translating research advances into improvements in long-term outcomes remain

The Retreatment Question: Research Suggests Benefits to Continuing Molecularly Targeted Therapy Beyond Progression

April 2nd 2014

The readministration of a cytotoxic antineoplastic agent is a well-established management paradigm in a number of malignancies, yet it is generally believed such a strategy may not prove beneficial if the patient experiences disease progression while receiving the therapy.

A Look at I-SPY 2: Novel Trial Design May Expand the Scope of Oncology Drug Development

April 2nd 2014

Amid a growing recognition of the need to improve the process of developing oncology drugs, the novel I-SPY 2 clinical trial in breast cancer has demonstrated the potential to deliver new, effective treatment options more rapidly to patients who would most benefit while dramatically reducing the time and costs currently required to evaluate experimental therapies.